¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immune response, primary"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • sensitization response
    ¹Î°¨È­¹ÝÀÀ
  • shortening response
    ´ÜÃà¹ÝÀÀ
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • unconditioned response
    ¹«Á¶°Ç¹ÝÀÀ
  • visual evoked response
    ½Ã°¢À¯¹ß¹ÝÀÀ
  • withdrawal response
    ±Ý´Ü¹ÝÀÀ
  • delayed primary suture
    Áö¿¬ÀÏÂ÷ºÀÇÕ
  • primary
    ÀÏÂ÷-, ¿ø¹ß-
  • primary action
    ÀÏÂ÷ÀÛ¿ë
  • primary affect hunger
    ÀÏÂ÷Á¤µ¿°¥¸Á, ÀÏÂ÷¾ÖÁ¤°¥¸Á
  • primary aldosteronism
    ¿ø¹ß¾Ëµµ½ºÅ×·ÐÁõ
  • primary amebic meningoencephalitis
    ¿ø¹ß¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • primary amenorrhea
    ¿ø¹ß¹«¿ù°æ
  • primary amnion
    ÀÏÂ÷¾ç¸·, ¿ø½Ã¾ç¸·
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ô·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • response prevention
    ¹ÝÀÀ¿¹¹æ
  • response
    ¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response rate
    ¹ÝÀÀ·ü
  • response set
    ¹ÝÀÀ¼¼Æ®
  • reticulocyte response
    ±×¹°¼¼Æ÷¹ÝÀÀ, ¸Á»óÀûÇ÷±¸¹ÝÀÀ
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • sensitization response
    ¹Î°¨¹ÝÀÀ
  • shortening response
    ´ÜÃà¹ÝÀÀ
  • startle response
    ³î¶÷¹ÝÀÀ
  • stereotyped response
    ÀÚµ¿¹Ýº¹¹ÝÀÀ, »óµ¿¹ÝÀÀ
  • subthreshold response
    ¹®ÅιعÝÀÀ
  • traction response
    ´ç±è¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • immune interferon (Interferon-¥ã)
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • immune memory
    ¸é¿ªÀû ±â¾ï(¡­ÑÀåã).
  • immune network
    ¸é¿ª¸Á
  • immune neutropenia
    ¸é¿ªÈ£Áß±¸°¨¼ÒÁõ.
  • immune phenomenon
    ¸é¿ªÇö»ó.
  • immune polysaccharides
    ¸é¿ª(¼º) ´Ù´ç·ù(¡­ÒýӨ׾).
  • immune precipitate
    ¸é¿ªÄ§°­¹°
  • immune protein
    ¸é¿ª´Ü¹éÁú.
  • immune reaction
    ¸é¿ª¹ÝÀÀ.
  • immune reactivity
    ¸é¿ª¹ÝÀÀ¼º.
  • immune ring
    ¸é¿ª°í¸®, ¸é¿ª·û
  • immune selection
    ¸é¿ª¼±ÅÃ
  • immune serum
    ¸é¿ªÇ÷û.
  • immune serum globulin
    ¸é¿ª Ç÷û ±Û·ÎºÒ¸°
  • immune serum globulin
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • immune selection
    ¸é¿ª¼±ÅÃ
  • immune serum
    ¸é¿ªÇ÷û.
  • immune serum globulin
    ¸é¿ª Ç÷û ±Û·ÎºÒ¸°
  • immune serum globulin
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°.
  • immune serum globulin transfusion
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°¼öÇ÷
  • immune state
    ¸é¿ª»óÅÂ
  • immune surveillance
    ¸é¿ª[ÇÐÀû]°¨½Ã±âÀü
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immune system
    ¸é¿ª°è(Øóæ¹Í§)
  • immune system
    ¸é¿ª°è.
  • immune thrombocytopenia
    ¸é¿ªÇ÷¼ÒÆÇ°áÇÌÁõ
  • immune tolerance
    ¸é¿ª°ü¿ë
  • immune-electron microscopy
    ¸é¿ªÀüÀÚÇö¹Ì°æ¹ý
  • immune-mediated hemolysis
    ¸é¿ª¸Å°³¼º ¿ëÇ÷
  • immune-mediated urticaria
    ¸é¿ª ¸Å°³ µÎµå·¯±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
ISG Immune Serum Globulin
ITP Idiopathic(Immune) Thrombocytopenic Purpura
RIG Rabies Immune Globulin
RIPA Radio-Immuno(= Immune)-Precipitation(Precipitin) Assay
TIG: (human) Tetanus Immune(Immuno-) Globulin ÆÄ»ódz Àΰ£ ¸é¿ª ±Û·ÎºÒ¸°
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
IS Immune suppression
ITP Immune thrombocytopenia
ITI Immune tolerance induction
IP immune precipitates
MEIA Microparticle Enzyme Immune Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primary foci
    ¿ø¹ß º´¼Ò
  • primary follicle
    ÀÏÂ÷ ³­Æ÷, ¿ø½Ã ³­Æ÷, ¿ø½Ã ¿©Æ÷
  • primary gain
    ÀÏÂ÷ À̵æ
  • primary headache
    ÀÏÂ÷ µÎÅë
  • primary hemorrhage
    ¿ø¹ß ÃâÇ÷, ¿ø¹ß¼º ÃâÇ÷, ÀÏÂ÷ ÃâÇ÷
  • primary herpes
    ¿ø¹ß¼º Æ÷Áø
  • primary hydrocephaly
    ¿ø¹ß ¼öµÎÁõ, ¿ø¹ß¼º ¼öµÎÁõ
  • primary hypertension
    ¿ø¹ß °íÇ÷¾ÐÁõ, ¿ø¹ß¼º °íÇ÷¾ÐÁõ
  • primary hypophosphatemia

    primary immune response (ÀÏÂ÷ ¸é¿ª ¹ÝÀÀ

  • primary inclusion
    ÀÏÂ÷ ºÀÀÔü
  • primary infection
    ¿ø¹ß¼º °¨¿°, ÀÏÂ÷ °¨¿°
  • primary insanity
    ¿ø¹ß Á¤½Åº´, ¿ø¹ß¼º Á¤½Åº´
  • primary ionization
    ÀÏÂ÷ ÀÌ¿ÂÈ­
  • primary lateral sclerosis
    ¿ø¹ß¼º Ãø»ö °æÈ­Áõ
  • primary lobule
    ÀÏÂ÷ ¼Ò¿±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
stringent response The cellular response to amino acid starvation that reduces the amount of ribosomes to what can be employed under the nutrient conditions.
(05 Mar 2000)
depletion response Subnormal metabolic response to trauma in a person whose physiologic processes are already depressed by disease.
(05 Mar 2000)
dose-response curve This is a graph to show the relation between the dose of a drug or other chemical and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(09 Oct 1997)
dose-response relationship Relationship in which a change in the amount, intensity, or duration of exposure is associated with a change in risk of a specified outcome.
(05 Mar 2000)
dose-response relationship, drug The relationship between the dose of an administered drug and the response of the organism to the drug.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
inflammatory response A part of innate immunity. Inflammation occurs when tissues are injured by viruses, bacteria, trauma, chemicals, heat, cold or any other harmful stimulus. Chemicals including bradykinin, histamine, serotonin and others are released by specialised cells. These chemicals attract tissue macrophages and white blood cells to localise in an area to engulf (phagocytize) and destroy foreign substances. A byproduct of this activity is the formation of pus--a combination of white blood cells, bacteria and foreign debris. The chemical mediators released during the inflammatory response give rise to the typical findings associated with inflammation.
(27 Sep 1997)
isomorphic response An isomorphic reaction seen in response to trauma in previously uninvolved sites of patients with skin diseases including psoriasis and lichen planus, typically with lesions in a linear pattern at sites of scratching or a scar.
Synonym: isomorphic response.
(05 Mar 2000)
oculomotor response Widespread myogenic potential evoked by visual stimuli.
(05 Mar 2000)
orienting response An aspect of attending in which an organism's initial response to a change or to a novel stimulus is such that the organism becomes more sensitive to the stimulation; e.g., dilation of the pupil of the eye in response to dim light.
Synonym: investigatory reflex, orienting response.
(05 Mar 2000)
overall response rate <pharmacology> Sum of complete and partial tumour responses seen in a study, divided by the number of evaluable patients.
(05 Jan 1998)
target response In conditioning, any behaviour or specific response chosen by the experimenter; its frequency is intended to increase or decrease by the judicious pairing with it of a reinforcer when it occurs.
Synonym: target behaviour, target response.
(05 Mar 2000)
th1 response <immunology> An acquired immune response whose most prominent feature is high cytotoxic T lymphocyte activity relative to the amount of antibody production. The Th1 response is promoted by CD4+ Th1 T-helper cells.
See: Th2 Response.
(09 Oct 1997)
th2 response <immunology> An acquired immune response whose most prominent feature is high antibody production relative to the amount of cytotoxic T lymphocyte activity The Th2 response is promoted by CD4+ Th2 T-helper cells.
See: TO Response.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á